Citius Prescription drugs, Inc. Submits Biologics License Software to the U.S. Food and Drug Administration for Denileukin Diftitox for the Remedy of Clients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
CRANFORD, N.J., Sept. 28, 2022 /PRNewswire/ -- Citius Prescribed drugs, Inc. ("Citius" or the "Enterprise") (Nasdaq: CTXR), a late-phase biopharmaceutical...